Bellerophon Therapeutics Inc (BLPH) Expected to Announce Earnings of -$0.12 Per Share

Brokerages expect Bellerophon Therapeutics Inc (NASDAQ:BLPH) to announce earnings per share of ($0.12) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics reported earnings of ($0.24) per share in the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 21st.

On average, analysts expect that Bellerophon Therapeutics will report full year earnings of ($0.47) per share for the current year. For the next financial year, analysts anticipate that the business will post earnings of ($0.52) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Bellerophon Therapeutics.

BLPH has been the topic of a number of recent research reports. Maxim Group initiated coverage on Bellerophon Therapeutics in a research note on Thursday, January 24th. They set a “buy” rating and a $3.00 price objective on the stock. ValuEngine lowered Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Bellerophon Therapeutics in a research note on Tuesday, January 29th. Finally, Zacks Investment Research raised Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Tuesday, January 1st.

In other news, Director Naseem Amin acquired 571,429 shares of the business’s stock in a transaction that occurred on Friday, January 25th. The shares were purchased at an average price of $0.70 per share, for a total transaction of $400,000.30. Following the acquisition, the director now owns 1,818,867 shares of the company’s stock, valued at $1,273,206.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 57.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of BLPH. VHCP Management III LLC purchased a new stake in Bellerophon Therapeutics during the 3rd quarter worth about $2,456,000. Renaissance Technologies LLC increased its holdings in shares of Bellerophon Therapeutics by 12.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,159,200 shares of the biotechnology company’s stock valued at $2,805,000 after acquiring an additional 126,300 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Bellerophon Therapeutics by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 27,027 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Bellerophon Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after acquiring an additional 25,300 shares during the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Bellerophon Therapeutics by 60.2% in the 4th quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 13,799 shares during the last quarter. Institutional investors own 50.16% of the company’s stock.

NASDAQ BLPH traded down $0.01 on Thursday, reaching $0.66. 1,525 shares of the company were exchanged, compared to its average volume of 504,191. The firm has a market capitalization of $46.18 million, a P/E ratio of -0.73 and a beta of 0.02. Bellerophon Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $3.30.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Featured Article: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit